Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00109928 · ClinicalTrials.gov registry record · Phase 2
S0350 Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Peripheral T-Cell Non-Hodgkin's Lymphoma
A Phase 2 study of Lymphoma, sponsored by SWOG Cancer Research Network.
- Completed
- Registry status
- Phase 2
- Development phase
- 34
- Enrollment target
- 20
- Study locations
NCT00109928: Completed Phase 2 study of Lymphoma, sponsored by SWOG Cancer Research Network.
NCT00109928 is a Phase 2 study of Lymphoma that has completed, run by SWOG Cancer Research Network. The registered enrollment target is 34 participants, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (93% lower). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00109928, a Phase 2 study of Lymphoma, has completed, sponsored by SWOG Cancer Research Network.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 34 participants
- Enrollment target
- 20
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy, such as cisplatin, etoposide, gemcitabine, and methylprednisolone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. PURPOSE: This phase II trial is studying how well combination chemotherapy works in treating patients with newly diagnosed stage II, stage III, or stage IV T-cell non-Hodgkin's lymphoma.
Primary Outcome
The overall survival rate is the percentage of patients who are alive 2 years after registration to the study. Overall survival is defined as the time between study registration and death due to any cause.
Conditions Studied
Interventions
- DRUG cisplatin
- DRUG methylprednisolone
- DRUG gemcitabine
- DRUG etoposide
Study Locations (20)
California
- Kaiser Permanente - Fremont - Fremont
- Kaiser Permanente Medical Center - Hayward - Hayward
- Kaiser Permanente Medical Center - Oakland - Oakland
- South Sacramento Kaiser-Permanente Medical Center - Sacramento
- Kaiser Permanente Medical Center - San Francisco Geary Campus - San Francisco
- Kaiser Permanente Medical Center - Santa Teresa - San Jose
- Kaiser Foundation Hospital - San Rafael - San Rafael
- Kaiser Permanente Medical Center - Santa Clara Kiely Campus - Santa Clara
- Kaiser Permanente Medical Center - Santa Rosa - Santa Rosa
- Kaiser Permanente Medical Center - South San Francisco - South San Francisco
- Kaiser Permanente Medical Facility - Stockton - Stockton
- Kaiser Permanente Medical Center - Vallejo - Vallejo
- Kaiser Permanente Medical Center - Walnut Creek - Walnut Creek
Illinois
- Decatur Memorial Hospital Cancer Care Institute - Decatur
- Cardinal Bernardin Cancer Center at Loyola University Medical Center - Maywood
- Regional Cancer Center at Memorial Medical Center - Springfield
Arizona
- Arizona Cancer Center at University of Arizona Health Sciences Center - Tucson
Arkansas
- Arkansas Cancer Research Center at University of Arkansas for Medical Sciences - Little Rock
Connecticut
- Saint Francis/Mount Sinai Regional Cancer Center at Saint Francis Hospital and Medical Center - Hartford
Florida
- M.D. Anderson Cancer Center at Orlando - Orlando
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2005-09 |
| Est. Completion | 2014-04 |
| Phase | Phase 2 |
What the finished NCT00109928 record still lists
NCT00109928 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 34 participants, a relatively small participant target, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (93% lower).
The record links to 1 condition, with Lymphoma appearing as the primary indexed condition, and to 4 interventions - of which cisplatin is the first listed.
NCT00109928 names 20 study sites across 6 states, led by California, Illinois, Arizona.
Frequently Asked Questions
What is clinical trial NCT00109928 about?
NCT00109928 is a clinical study titled "S0350 Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Peripheral T-Cell Non-Hodgkin's Lymphoma". RATIONALE: Drugs used in chemotherapy, such as cisplatin, etoposide, gemcitabine, and methylprednisolone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cance...
What is the current status of trial NCT00109928?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 34 participants. The study started on 2005-09. Estimated completion is 2014-04.
What conditions does trial NCT00109928 study?
This clinical trial studies the following conditions: Lymphoma.
What interventions are being tested in trial NCT00109928?
The interventions under investigation include: cisplatin (DRUG), methylprednisolone (DRUG), gemcitabine (DRUG), etoposide (DRUG).
Who is sponsoring clinical trial NCT00109928?
This trial is sponsored by SWOG Cancer Research Network, which has 270 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00109928 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00109928's enrollment target sits among peer trials
34 203rd of 299 higher than 94 of 299 other Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
RECRUITING · Phase 2
-
A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy
RECRUITING · Phase 2
-
Odronextamab in Low Tumor Volume Advanced FL
RECRUITING · Phase 2
-
A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma
RECRUITING · Phase 2
-
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
RECRUITING · Phase 2
-
Pilot Trial of Fecal Microbiota Transplantation for Lymphoma Patients Receiving Axicabtagene Ciloleucel Therapy.
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02897063 · 34 participants · Phase 1
Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure
- NCT03906617 · 34 participants · Phase 4
Bupivacaine/Epinephrine +Dexamethasone vs. Liposomal Bupivacaine
- NCT03992378 · 34 participants · NA
Neuromodulation to Regulate Inflammation and Autonomic Imbalance in Sepsis
- NCT04047849 · 34 participants · Phase 4
Latency Antibiotics in Previable PPROM, 18 0/7- 22 6/7 WGA
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia